We could not find any results for:
Make sure your spelling is correct or try broadening your search.
vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (... vTv Therapeutics Inc operates in the United States healthcare sector. Its key business includes the development of orally administered small molecule drug candidates for the treatment of neurological disorders such as Alzheimer's disease. Its major drug candidate to treat Alzheimer's is azeliragon (TTP488), an orally administered drug. Its other products include TTP399, type II diabetes drug candidate. TTP399 is also an orally administered drug that targets the glucagon-like peptide-1 receptor. It also has over three additional programs in various stages of clinical development for the prevention of muscle weakness and the treatment of inflammatory disorders. Show more
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -1.39 | -8.22485207101 | 16.9 | 16.9 | 14.04 | 18595 | 14.99591075 | CS |
4 | 1.75 | 12.7180232558 | 13.76 | 18.31 | 12.62 | 42776 | 14.64413516 | CS |
12 | 0.47 | 3.125 | 15.04 | 18.31 | 12.62 | 27172 | 14.73745817 | CS |
26 | -12.1 | -43.8247011952 | 27.61 | 27.61 | 12.1201 | 27115 | 16.26914215 | CS |
52 | 5.86 | 60.725388601 | 9.65 | 30.99 | 7.38 | 38060 | 15.87960835 | CS |
156 | -38.09 | -71.0634328358 | 53.6 | 56 | 7.38 | 186190 | 30.15364766 | CS |
260 | -44.49 | -74.15 | 60 | 205.2 | 7.38 | 900381 | 99.45929724 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions